InflaRx (NASDAQ:IFRX) Issues Earnings Results, Meets Expectations

InflaRx (NASDAQ:IFRX) announced its quarterly earnings results on Thursday. The company reported ($0.17) EPS for the quarter, hitting analysts’ consensus estimates of ($0.17), Zacks reports. The business had revenue of ($0.04) million during the quarter, compared to analysts’ expectations of $0.03 million.

InflaRx Price Performance

Shares of NASDAQ IFRX opened at $0.91 on Friday. InflaRx has a 1 year low of $0.71 and a 1 year high of $1.94. The stock has a market cap of $61.06 million, a P/E ratio of -1.34 and a beta of 1.48. The firm has a 50-day moving average of $0.93 and a 200 day moving average of $1.15.

Analysts Set New Price Targets

Several research analysts have commented on IFRX shares. Leerink Partners restated a “market perform” rating and issued a $2.00 price objective (down from $5.00) on shares of InflaRx in a report on Wednesday, December 3rd. Weiss Ratings reiterated a “sell (d-)” rating on shares of InflaRx in a research report on Monday, December 29th. Raymond James Financial reissued an “outperform” rating on shares of InflaRx in a research note on Wednesday, December 31st. HC Wainwright reaffirmed a “buy” rating and set a $6.00 price objective on shares of InflaRx in a research report on Tuesday, December 30th. Finally, Guggenheim reduced their target price on InflaRx from $22.00 to $14.00 and set a “buy” rating on the stock in a report on Friday. Five analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $6.17.

Hedge Funds Weigh In On InflaRx

A number of institutional investors and hedge funds have recently made changes to their positions in the business. Suvretta Capital Management LLC raised its stake in InflaRx by 22.4% during the fourth quarter. Suvretta Capital Management LLC now owns 7,933,910 shares of the company’s stock valued at $8,013,000 after buying an additional 1,450,000 shares during the last quarter. Bank of America Corp DE purchased a new stake in shares of InflaRx in the third quarter worth $3,316,000. Woodline Partners LP purchased a new stake in shares of InflaRx in the first quarter worth $766,000. Adage Capital Partners GP L.L.C. bought a new position in shares of InflaRx during the second quarter valued at $262,000. Finally, Squarepoint Ops LLC increased its holdings in shares of InflaRx by 72.0% during the fourth quarter. Squarepoint Ops LLC now owns 324,349 shares of the company’s stock valued at $328,000 after acquiring an additional 135,826 shares in the last quarter. Institutional investors own 42.39% of the company’s stock.

InflaRx Company Profile

InflaRx N.V. is a clinical?stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapies targeting the complement system, with an emphasis on the complement?1a (C5a) pathway. The company’s lead product candidate, vilobelimab (IFX?1), is a monoclonal antibody designed to selectively inhibit C5a, a potent pro?inflammatory peptide implicated in a range of autoimmune and inflammatory diseases. InflaRx seeks to address high?unmet medical needs by advancing treatments for conditions such as hidradenitis suppurativa, pyoderma gangrenosum and other rare and severe inflammatory disorders.

Vilobelimab has been evaluated in multiple Phase II trials, demonstrating proof of concept in reducing key inflammatory markers and improving clinical outcomes.